LumiraDx Limited (LMDX)

NASDAQ: LMDX · IEX Real-Time Price · USD
0.610
-0.130 (-17.57%)
At close: Mar 24, 2023, 4:00 PM
0.629
+0.019 (3.13%)
After-hours: Mar 24, 2023, 7:59 PM EDT
-17.57%
Market Cap 203.20M
Revenue (ttm) 254.48M
Net Income (ttm) -449.38M
Shares Out 333.12M
EPS (ttm) -1.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 515,210
Open 0.718
Previous Close 0.740
Day's Range 0.590 - 0.763
52-Week Range 0.590 - 8.260
Beta 1.16
Analysts Buy
Price Target 3.56 (+483.61%)
Earnings Date May 10, 2023

About LMDX

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solut... [Read more]

Sector Healthcare
Founded 2014
Employees 1,513
Stock Exchange NASDAQ
Ticker Symbol LMDX
Full Company Profile

Financial Performance

In 2022, LumiraDx's revenue was $254.48 million, a decrease of -39.62% compared to the previous year's $421.43 million. Losses were -$449.38 million, 345.2% more than in 2021.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for LMDX stock is "Buy." The 12-month stock price forecast is $3.56, which is an increase of 483.61% from the latest price.

Price Target
$3.56
(483.61% upside)
Analyst Consensus: Buy
Stock Forecasts

News

LumiraDx Limited (LMDX) Reports Q4 Loss, Tops Revenue Estimates

LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -68.42% and 7.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

5 days ago - Zacks Investment Research

LumiraDx Reports Fourth Quarter and Full Year 2022 Results

LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full...

5 days ago - GlobeNewsWire

LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21

LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 f...

1 week ago - GlobeNewsWire

LumiraDx to Present at Raymond James Institutional Investors Conference

LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James Institu...

3 weeks ago - GlobeNewsWire

LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements

LONDON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has rega...

1 month ago - GlobeNewsWire

LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK

LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of car...

1 month ago - GlobeNewsWire

LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it...

1 month ago - GlobeNewsWire

LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test

Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test's ongoing development and future launch into developing countries Company receives $14.2M in grants fr...

3 months ago - GlobeNewsWire

Point of Care (POC) Survey Reveals Majority of U.K. Clinicians Endorse Climate Benefits of POC Through Reduction of Carbon Emissions and Anticipate Future Growth of POC Testing to Come from Community Settings

LumiraDx shares these and other findings from its first annual U.K. survey “Point of Care Diagnostics: A Clinicians View” LumiraDx shares these and other findings from its first annual U.K. survey “Po...

3 months ago - GlobeNewsWire

Latest Clinicians' U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers

LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” LumiraDx shares these and other findings from its second annual U.S. survey ...

3 months ago - GlobeNewsWire

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa  Early customers include GP offices and other community-based healthcare settings Latest figures, released as part of...

4 months ago - PRNewsWire

LumiraDx Limited (LMDX) Reports Q3 Loss, Tops Revenue Estimates

LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -56.67% and 46.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

LumiraDx Reports Third Quarter 2022 Results

Progress on Near-Term Growth Opportunities and Cost Savings Progress on Near-Term Growth Opportunities and Cost Savings

4 months ago - GlobeNewsWire

LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9

LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on ...

5 months ago - GlobeNewsWire

LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry

The research company recognizes LumiraDx for uniquely leveraging its technology to meet customers' needs and capitalizing on new growth opportunities The research company recognizes LumiraDx for uniqu...

5 months ago - GlobeNewsWire

LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance

Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” Testing Times Re...

6 months ago - GlobeNewsWire

LumiraDx Reports Second Quarter 2022 Results

Strong Pipeline Progress and Commercialization Priorities for Newly Authorized Products Strong Pipeline Progress and Commercialization Priorities for Newly Authorized Products

7 months ago - GlobeNewsWire

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18

LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on...

8 months ago - GlobeNewsWire

LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement

LONDON , July 21, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced the pricing of its underwritten public offering of 43...

8 months ago - PRNewsWire

LumiraDx Announces Proposed Public Offering of Common Shares

LONDON , July 19, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced that it has commenced an underwritten public offering...

8 months ago - PRNewsWire

LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System

Next-generation antigen test system built on more than eight years of research and backed by industry leading microfluidic experts The Amira System includes the Amira Analyzer, Amira SARS-CoV-2 Ag tes...

10 months ago - PRNewsWire

Why LumiraDx Shares Are Rising Today

LumiraDx Ltd (NASDAQ: LMDX) shares are trading higher by 10.31% at $4.28 after the company announced it achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-...

10 months ago - Benzinga

LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete

LONDON , June 8, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX) today announced that it has achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR...

10 months ago - PRNewsWire

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are desig...

10 months ago - PRNewsWire

LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform

Rapid microfluidic immunofluorescence assay intended for the monitoring of individuals with diabetes, and as an aid in screening and identifying patients who may be at risk for developing diabetes The...

10 months ago - PRNewsWire